Lipoprotein metabolism and lipid management in chronic kidney disease.

Dyslipidemia is an established cardiovascular (CV) risk factor in the general population. In chronic kidney disease (CKD), however, epidemiologic studies ([1][1]–[3][2]) and clinical trials ([4][3]–[12][4]) have raised uncertainties regarding the impact of dyslipidemia on clinical outcomes and,

[1]  W. Feeman.  Statin-fibrate combination therapy. , 2008, The American journal of cardiology.

[2]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[3]  F. Kronenberg,et al.  In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. , 2007, Kidney international.

[4]  C. Wanner,et al.  The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. , 2007, International journal of cardiology.

[5]  Richard Platt,et al.  Risk factors for statin‐associated rhabdomyolysis , 2007, Pharmacoepidemiology and drug safety.

[6]  F. Kronenberg,et al.  Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria Published, JLR Papers in Press, June 20, 2006. , 2006, Journal of Lipid Research.

[7]  Mason W Freeman,et al.  Scavenger receptors in atherosclerosis: beyond lipid uptake. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[8]  C. Schaefer,et al.  Direct Adsorption of Low‐Density Lipoprotein by DALI‐LDL‐Apheresis: Results of a Prospective Long‐term Multicenter Follow‐up Covering 12 291 Sessions , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  F. Kronenberg,et al.  Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  J. Avorn,et al.  Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  F. Kronenberg,et al.  Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. , 2006, Journal of the American Society of Nephrology : JASN.

[12]  F. Kronenberg,et al.  Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  M. Hayden,et al.  Gene therapy for lipoprotein lipase deficiency: working toward clinical application. , 2005, Human gene therapy.

[14]  T. Lehtimäki,et al.  HDL enhances oxidation of LDL in vitro in both men and women , 2005, Lipids in Health and Disease.

[15]  P. Raggi,et al.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.

[16]  F. Kronenberg,et al.  Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. , 2005, Kidney international.

[17]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[18]  F. Zannad,et al.  Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study , 2005, Current controlled trials in cardiovascular medicine.

[19]  P. Raggi,et al.  Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. , 2005, American heart journal.

[20]  J. van der Palen,et al.  Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial , 2005, Journal of internal medicine.

[21]  C. Böger,et al.  Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. , 2005, European journal of medical research.

[22]  F. Kronenberg.  Dyslipidemia and nephrotic syndrome: recent advances. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[23]  N. Powe,et al.  High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.

[24]  Dick M. Goedhart,et al.  Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). , 2005, The American journal of cardiology.

[25]  J. Bragg-Gresham,et al.  HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[27]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[28]  M. Sarnak,et al.  Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. , 2004, Metabolism: clinical and experimental.

[29]  P. Dupont,et al.  Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. , 2004, Clinical nephrology.

[30]  M. Bennett,et al.  Role of apoptosis in atherosclerosis and its therapeutic implications. , 2004, Clinical science.

[31]  C. Wanner,et al.  Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  John Simes,et al.  Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.

[33]  F. Kronenberg.  Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease , 2004, Expert review of cardiovascular therapy.

[34]  H. Bloomfield,et al.  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. , 2004, Kidney international.

[35]  J. Mckenney.  New perspectives on the use of niacin in the treatment of lipid disorders. , 2004, Archives of internal medicine.

[36]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. , 2004, Kidney international.

[37]  A. D'Angelo,et al.  Lipoprotein(a)-Associated Atherothrombotic Risk in Hemodialysis Patients , 2004, American Journal of Nephrology.

[38]  F. Kronenberg,et al.  The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. , 2004, Kidney international.

[39]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[40]  M. Linton,et al.  Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? , 2003, Molecular interventions.

[41]  A. Krentz.  Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes , 2003, Diabetes, obesity & metabolism.

[42]  T. Littlewood,et al.  Apoptotic cell death in atherosclerosis , 2003, Current opinion in lipidology.

[43]  F. Kronenberg,et al.  Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation , 2003, European Journal of Human Genetics.

[44]  G. Asmus,et al.  Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. , 2003, Journal of the American Society of Nephrology : JASN.

[45]  C. Baigent,et al.  Study of Heart and Renal Protection (SHARP). , 2003, Kidney international. Supplement.

[46]  A. Jardine,et al.  Why do we need a statin trial in hemodialysis patients? , 2003, Kidney international. Supplement.

[47]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[48]  W. März,et al.  Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.

[49]  F. Sacks,et al.  Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency , 2003, Annals of Internal Medicine.

[50]  K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  N. Powe,et al.  Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study , 2002, Circulation.

[52]  M. Navab,et al.  Oxidized lipids as mediators of coronary heart disease , 2002, Current opinion in lipidology.

[53]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[54]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[55]  A. R. Morton,et al.  Apolipoprotein(a) Phenotype and Lipoprotein(a) Level Predict Peritoneal Dialysis Patient Mortality , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[56]  N. Powe,et al.  Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. , 2002, Journal of the American Society of Nephrology : JASN.

[57]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[58]  F. Kronenberg,et al.  Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. , 2002, Journal of the American Society of Nephrology : JASN.

[59]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[60]  B. Kestenbaum,et al.  HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.

[61]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[62]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[63]  M. Emoto,et al.  Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. , 2001, Journal of the American Society of Nephrology : JASN.

[64]  W. Bloembergen,et al.  Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. , 2001, Journal of the American Society of Nephrology : JASN.

[65]  Y. Zhao,et al.  The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. , 2001, Chinese medical journal.

[66]  R. Virmani,et al.  Apoptosis in atherosclerosis. Does it contribute to plaque instability? , 2001, Cardiology clinics.

[67]  P. Wilson,et al.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. , 2001, Atherosclerosis.

[68]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[69]  M. Haberal,et al.  Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[70]  F. Kronenberg,et al.  Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. , 2000, Journal of the American College of Cardiology.

[71]  M. Rocco,et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.

[72]  S. Grundy,et al.  Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. , 2000, Atherosclerosis.

[73]  F. Kronenberg,et al.  Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[74]  Y. Kawaguchi,et al.  Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. , 1999, Kidney international. Supplement.

[75]  S. Watanabe,et al.  Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. , 1999, Kidney international. Supplement.

[76]  H. Otani,et al.  Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. , 1999, Kidney international. Supplement.

[77]  S. Nishi,et al.  Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. , 1999, Kidney international. Supplement.

[78]  F. Kronenberg,et al.  Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. , 1999, Atherosclerosis.

[79]  H. Milionis,et al.  Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[80]  F. Kronenberg,et al.  The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. , 1999, Journal of the American Society of Nephrology : JASN.

[81]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[82]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[83]  F. Kronenberg,et al.  Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). , 1999, Wiener klinische Wochenschrift.

[84]  C. Knoop,et al.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[85]  R. Schwartz,et al.  Apoptosis. Basic concepts and implications in coronary artery disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[86]  R. Havel,et al.  Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. , 1998, Clinical chemistry.

[87]  P. Marquet,et al.  Decrease of serum paraoxonase activity in chronic renal failure. , 1998, Journal of the American Society of Nephrology : JASN.

[88]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[89]  T. Rabelink,et al.  Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[90]  T. Shoji,et al.  Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. , 1998, Journal of the American Society of Nephrology : JASN.

[91]  P. Stenvinkel,et al.  Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. , 1998, Kidney international.

[92]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[93]  A. Tall,et al.  Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. , 1998, Annual review of nutrition.

[94]  F. Kronenberg,et al.  Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. , 1997, Journal of the American Society of Nephrology : JASN.

[95]  M. Árnadóttir.  Pathogenesis of dyslipoproteinemia in renal insufficiency: the role of lipoprotein lipase and hepatic lipase. , 1997, Scandinavian journal of clinical and laboratory investigation.

[96]  C. Gazzaruso,et al.  Increased plasma concentrations of lipoprotein(a) for every phenotype of apolipoprotein(a) in patients with chronic renal failure treated by hemodialysis , 1996 .

[97]  K. Iseki,et al.  Predictors of stroke in patients receiving chronic hemodialysis. , 1996, Kidney international.

[98]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[99]  Shin-Wook Kang,et al.  Impact of Nutritional Status on Serum Lipoprotein (A) Concentration in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[100]  F. Kronenberg,et al.  Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[101]  M. Seed,et al.  Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[102]  C. Wanner,et al.  Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[103]  M. Kishino,et al.  Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[104]  G. Schonfeld,et al.  The effects of fibrates on lipoprotein and hemostatic coronary risk factors. , 1994, Atherosclerosis.

[105]  F. Kronenberg,et al.  Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[106]  F. Kronenberg,et al.  Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[107]  P. Gambert,et al.  Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. , 1994, Journal of lipid research.

[108]  D. Rader,et al.  Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome , 1993, Annals of Internal Medicine.

[109]  A. Cheung,et al.  Atherogenic lipids and lipoproteins in hemodialysis patients. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[110]  F. Kronenberg,et al.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). , 1993, The Journal of clinical investigation.

[111]  M. Sentí,et al.  Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[112]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[113]  R. Krauss,et al.  Differential effects of nicotinic acid in subjects with different LDL subclass patterns. , 1992, Atherosclerosis.

[114]  M. Sentí,et al.  Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. , 1992, Kidney international.

[115]  E. Lowrie,et al.  Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. , 1992, Seminars in nephrology.

[116]  G. Utermann,et al.  Plasma apolipoprotein A‐IV metabolism in patients with chronic renal disease , 1992, European journal of clinical investigation.

[117]  A. del Río.  [Lipoprotein (a)]. , 1991, Medicina clinica.

[118]  P. Attman,et al.  Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis. , 1991, Nephron.

[119]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[120]  J. Fruchart,et al.  Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.

[121]  E G Lowrie,et al.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[122]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[123]  Ronald M. Krauss,et al.  A PROPOSED GENETIC MARKER FOR CORONARY HEART DISEASE RISK , 1990 .

[124]  A. Hamsten,et al.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.

[125]  B. Gordon,et al.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[126]  G. Rosenhamer,et al.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.

[127]  S. Grundy,et al.  Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. , 1987, The American journal of medicine.

[128]  S. Grundy,et al.  Fibric acids: effects on lipids and lipoprotein metabolism. , 1987, The American journal of medicine.

[129]  M. Seishima,et al.  An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[130]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[131]  A. Gotto,et al.  Apolipoprotein A-IV. A determinant for binding and uptake of high density lipoproteins by rat hepatocytes. , 1986, The Journal of biological chemistry.

[132]  M. Lefevre,et al.  The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. , 1986, Biochimica et biophysica acta.

[133]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[134]  J. Albers,et al.  Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. , 1985, Biochimica et biophysica acta.

[135]  R. Zechner,et al.  The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. , 1985, Journal of lipid research.

[136]  G. Utermann,et al.  Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[137]  M. Brown,et al.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.

[138]  P. Nestel,et al.  Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.

[139]  P. Degoulet,et al.  Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.

[140]  H. Mabuchi,et al.  Intermediate‐density Lipoprotein and Cholesterol‐rich Very Low Density Lipoprotein in Angiographically Determined Coronary Artery Disease , 1981, Circulation.

[141]  A Cryer,et al.  Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. , 1981, The International journal of biochemistry.

[142]  L. Simons,et al.  Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. , 1980, Kidney international.

[143]  D. Cattran,et al.  Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis. , 1976, Annals of Internal Medicine.

[144]  D. Bilheimer,et al.  On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. , 1973, Biochimica et biophysica acta.

[145]  F. del Greco,et al.  Lipid abnormalities in renal disease. , 1972, Annals of clinical laboratory science.